A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 5, 2013, Pages 831-837

  Mark, Tomer M ^a   Reid, Whitney ^a   Niesvizky, Ruben ^a   Gergis, Usama ^a   Pearse, Roger ^a   Mayer, Sebastian ^a   Greenberg, June ^a   Coleman, Morton ^a   Van Besien, Koen ^a   Shore, Tsiporah ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Autologous; Bendamustine; Conditioning; Melphalan; Multiple myeloma; Transplantation

Indexed keywords

ACICLOVIR; BENDAMUSTINE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; LEVOFLOXACIN; MELPHALAN; PLERIXAFOR;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTHRALGIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; BLEPHARITIS; BLURRED VISION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CARDIOTOXICITY; CLINICAL ARTICLE; COLITIS; CONDITIONING; CONSTIPATION; COUGHING; DELIRIUM; DIARRHEA; DISEASE EXACERBATION; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; DYSPNEA; DYSURIA; ENTERITIS; FEMALE; FLUSHING; FOLLOW UP; GENERALIZED WEAKNESS; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXIA; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEUTROPHIL; NONHODGKIN LYMPHOMA; ORAL THRUSH; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PSYCHOSIS; RECTUM HEMORRHAGE; SEPSIS; SIDE EFFECT; SINUS TACHYCARDIA; SINUSITIS; SOLID TUMOR; THORAX PAIN; THROMBOCYTE; TINEA CRURIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; NITROGEN MUSTARD COMPOUNDS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 84876273138     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.02.013     Document Type: Article

References (31)

1. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996, 335:91-97.
2. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
3. Moreau P., Avet-Loiseau H., Harousseau J.L., Attal M. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol 2011, 29:1898-1906.
4. Lahuerta J.J., Mateos M.V., Martinez-Lopez J., et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008, 26:5775-5782.
5. Harousseau J.L., Attal M., Avet-Loiseau H., et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010, 28:4621-4629.
6. Harousseau J.L., Attal M., Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009, 114:3139-3146.
7. Chanan-Khan A.A., Giralt S. Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents. J Clin Oncol 2010, 28:2612-2624.
8. Barlogie B., Anaissie E., Haessler J., et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 2008, 113:355-359.
9. Moreau P., Hullin C., Garban F., et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood 2006, 107:397-403.
10. 2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica 2010, 95:1913-1920.
11. Leoni L.M., Bailey B., Reifert J., et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008, 14:309-317.
12. Ponisch W., Mitrou P.S., Merkle K., et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006, 132:205-212.
13. Grey-Davies E., Bosworth J.L., Boyd K.D., et al. Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. Br J Haematol 2012, 156:552-555. [letter].
14. Damaj G., Malard F., Hulin C., et al. Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leuk Lymphoma 2012, 53:632-634.
15. Lentzsch S., O'Sullivan A., Kennedy R.C., et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase I/II open-label, dose escalation study. Blood 2012, 119:4608-4613.
16. Knop S., Straka C., Haen M., et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005, 90:1287-1288.
17. Visani G., Malerba L., Stefani P.M., et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011, 118:3419-3425.
18. Rasschaert M., Schrijvers D., Van den Brande J., et al. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. Anticancer Drugs 2007, 18:587-595.
19. Rajkumar S.V., Harousseau J.L., Durie B., et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011, 117:4691-4695.
20. Mark T., Ounsafi I., Christos P., et al. The Association of Ki67 Percent Positivity and Clinical Outcomes in the Upfront Treatment of Multiple Myeloma. Haematologica [abstract] 2011, 96. 13th International Myeloma Workshop.
21. Moreau P., Facon T., Attal M., et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002, 99:731-735.
22. Desikan K.R., Barlogie B., Jagannath S., et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998, 16:1547-1553.
23. Attal M., Harousseau J.L., Facon T., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003, 349:2495-2502.
24. 2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant 2004, 33:781-787.
25. 2 as a preparative regimen for patients with multiple myeloma undergoing autologous stem cell transplantation. Blood [abstract] 2012, 120:2009.
26. Leoni L.M., Bailey B., Niemeyer C.C., et al. In vitro and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells. AACR Meeting Abstracts 2004, 278.
27. Blijlevens N., Schwenkglenks M., Bacon P., et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy-European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008, 26:1519-1525.
28. Grazziutti M.L., Dong L., Miceli M.H., et al. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant 2006, 38:501-506.
29. Blijlevens N., de Chateau M., Krivan G., et al. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden. Bone Marrow Transplant 2012 Dec 17, [Epub ahead of print]. 10.1038/bmt.2012.257.
30. Abidi M.H., Agarwal R., Tageja N., et al. A phase 1 dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function. Biol Blood Marrow Transplant 2012, 19:56-61.
31. Avivi I., Avraham S., Koren-Michowitz M., et al. Oral integrity and salivary profile in myeloma patients undergoing high-dose therapy followed by autologous SCT. Bone Marrow Transplant 2009, 43:801-806.